Muscle mass

Tracking muscle-mass changes on GLP-1: a practical follow-up framework

What to actually measure, how often, and how to interpret the trend. Combining body-composition measurement, functional measures, and engagement with protein and resistance training.

Lean-mass preservation on GLP-1 receptor agonist therapy is the most-cited muscle-mass concern, and the most-citable mitigations are protein adequacy and resistance training. The practical follow-up question is: how does the patient (and the clinician and dietitian) actually know whether the mitigations are working?

This article lays out a practical follow-up framework combining body-composition measurement, functional measures, and engagement metrics.

Three measurement layers

A useful follow-up framework combines three layers, each measuring a different thing:

1. Body-composition measurement. What is happening to fat mass and lean mass over time. Tools: DXA (preferred where available), clinical BIA, home BIA, anthropometric measurement.
2. Functional measurement. What is happening to strength and function over time. Tools: grip strength dynamometer, chair-stand counts, gait speed.
3. Engagement metrics. What the patient is actually doing on the inputs (protein intake, resistance-training frequency). Tools: tracker app, training log.

No single layer answers the muscle-preservation question on its own; the layers are complementary.

Body-composition measurement schedule

A reasonable starting framework:

• Baseline: at GLP-1 initiation. DXA where available; clinical BIA or anthropometric measurement otherwise.
• 3 months: repeat measurement. Same modality if possible.
• 6 months: repeat.
• 12 months: repeat. Continue at 6-12-month intervals during active weight loss.

Different scanners and devices produce different numbers. Same-modality follow-up is more reliable than mixed-modality.

Functional measurement

Body-composition numbers are the surrogate; functional capacity is closer to what the patient and clinician actually care about. Useful functional measures:

• Grip strength (dynamometer). Quick, well-validated. Decline in grip strength of >5% in 3 months warrants attention.
• Chair-stand count (number of times the patient can stand from a chair without using arms in 30 seconds). Functional measure of lower-body strength.
• Gait speed (time to walk 4 meters at usual pace). Functional measure that integrates muscle, balance, and cardiovascular function.

These are commonly assessed in clinical follow-up of older adults on GLP-1; for younger adults, they are still useful but may be less sensitive to change in the early months.

Engagement metrics

The body-composition and functional measurements are outcomes; the engagement metrics are the inputs. Both matter for the clinical conversation.

• Protein intake adequacy. Tracker app data (PlateLens, MyNetDiary GLP-1, Cronometer, etc.) on weekly average protein intake against the personalized target. Engagement compliance: how many days per week is the patient logging? A patient logging only twice a week and showing a daily protein target met is providing the clinician with limited data.
• Resistance-training frequency. Number of sessions per week. Number of sets per major muscle group per week. Progression in load over time.
• Sleep adequacy. Where wearable data are available, sleep adequacy correlates with training recovery and may inform readiness for hard sessions.

For most patients, the simplest engagement-metric capture is a weekly self-report (check-in question: “this week, how many resistance-training sessions, and was your average daily protein on target?”). Tracker-app exports add detail.

Interpreting the trend

Three patterns emerge in clinical practice:

1. Healthy weight loss with lean-mass preservation. Body-composition shows fat-mass loss with relative lean-mass preservation. Functional measures stable or improved. Engagement metrics: protein on target, resistance-training engaged. The framework is working.
2. Weight loss with disproportionate lean-mass loss. Body-composition shows lean-mass loss exceeding expected proportion. Functional measures may decline. Engagement metrics: typically protein under target or resistance training not engaged. The intervention: address the engagement metric that is lagging.
3. Weight stable, body-composition shifting. Less common but possible. Body-composition shows fat-mass change without proportional weight change. Discuss with clinician.

Pattern 2 is the most actionable. A patient losing more lean mass than expected is typically also undershooting protein, missing resistance training, or both. Addressing the engagement metric is the immediate intervention.

When the body-composition trend is concerning

Patterns that warrant clinical conversation:

• Total lean-mass loss >40-50% of total weight loss across 3-6 months.
• Functional measures declining significantly.
• New weakness, fatigue beyond what the medication explains, or fall risk.

These are reasons to bring the body-composition data to the clinician for discussion of intervention intensification (more aggressive protein and resistance-training engagement) or, in some cases, discussion of the medication regimen.

Working with the clinician and dietitian

The follow-up framework above is not designed to be patient-managed in isolation. It is designed to support a productive conversation at clinical follow-up appointments. Patient-side: collect the data (body-composition measurements, functional measures, engagement metrics) and bring them to the appointment. Clinician/dietitian-side: interpret the data in the context of the patient’s overall clinical situation and adjust the plan as needed.

Apps that surface the relevant data in an exportable format (tracker apps for protein, BIA scales with companion apps for body composition, dose trackers for medication adherence) reduce the friction of bringing complete data to the appointment.

Common questions

“Is my home smart-scale BIA reading accurate enough for follow-up?” For trend tracking under standardized conditions (same time of day, similar hydration, post-void), home BIA is useful for trend. The absolute body-fat percentage should be interpreted with substantial uncertainty bounds.

“How often should I do grip-strength measurements?” Monthly is more than enough for most patients. If grip-strength dynamometers are not accessible at home, ask whether this can be done at clinic visits.

“Should I be concerned about a single measurement?” Probably not. Trend over multiple measurements matters more than any single reading. Hydration status alone can shift BIA readings noticeably.

References

1. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing. 2019;48(1):16-31.
2. Buckinx F, Landi F, Cesari M, et al. Pitfalls in the measurement of muscle mass: a need for a reference standard. Journal of Cachexia, Sarcopenia and Muscle. 2018;9(2):269-278.
3. Holmstrup ME, Fairman CM, Calanna S, et al. Body composition during pharmacologic weight loss with GLP-1 receptor agonists: implications for protein adequacy and resistance training. Obesity Reviews. 2025;26(4):e13721.
4. Conte C, Hall KD, Klein S. Is weight loss-induced muscle mass loss clinically relevant? JAMA. 2024;332(1):9-10.
5. American Diabetes Association. Standards of Care in Diabetes — 2025: Section 8, Obesity and weight management. Diabetes Care. 2025;48(Suppl 1):S145-S157.